title: Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial.
abstract: A multicenter, randomized placebo-controlled double-blind trial of nimodipine in poor-grade aneurysm patients was carried out in 17 Canadian hospitals. Of 188 patients enrolled in the trial, 32 were excluded for protocol violations and two were excluded due to statistical considerations, leaving 154 patients for valid outcome analysis. Nimodipine treatment was associated with a significantly better outcome (p less than 0.001): 21 (29.2%) of 72 nimodipine-treated patients had a good outcome at 3 months after subarachnoid hemorrhage (SAH) compared to eight (9.8%) of 82 placebo-treated patients. Delayed ischemic deficits from vasospasm alone were significantly less frequent in the nimodipine group (p less than 0.05) with permanent deficits occurring in five nimodipine-treated patients (6.9%) and in 22 placebo-treated patients (26.8%). Improvement in the good outcome rate and reduction in delayed ischemic deficits from vasospasm alone occurred in both Grade 3 and 4 patients, with no difference between nimodipine- and placebo-treated patients being found in Grade 5 patients. Repeat angiography after Day 4 was carried out in 124 patients. There was no significant difference in the incidence of moderate or severe diffuse spasm, which was seen in 64.3% of nimodipine-treated patients and 66.2% of placebo-treated patients. The authors conclude that nimodipine treatment in poor-grade patients with SAH results in an increase in the number of good outcomes and a reduction in the incidence of delayed neurological deterioration due to vasospasm. This effect occurs by a mechanism other than prevention of large-vessel spasm as visualized on angiography.
authors.affiliation: Division of Neurosurgery, University of Alberta Health Science Centre, Edmonton, Canada.
authors.forename: K C
authors.initials: KC
authors.lastname: Petruk
authors.forename: M
authors.initials: M
authors.lastname: West
authors.forename: G
authors.initials: G
authors.lastname: Mohr
authors.forename: B K
authors.initials: BK
authors.lastname: Weir
authors.forename: B G
authors.initials: BG
authors.lastname: Benoit
authors.forename: F
authors.initials: F
authors.lastname: Gentili
authors.forename: L B
authors.initials: LB
authors.lastname: Disney
authors.forename: M I
authors.initials: MI
authors.lastname: Khan
authors.forename: M
authors.initials: M
authors.lastname: Grace
authors.forename: R O
authors.initials: RO
authors.lastname: Holness
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D002545:Brain Ischemia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D002533:Cerebral Angiography; D002544:Cerebral Infarction / Q000000981:diagnostic imaging / Q000209:etiology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D002546:Ischemic Attack, Transient / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control; D008875:Middle Aged; D009553:Nimodipine / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013345:Subarachnoid Hemorrhage; D014057:Tomography, X-Ray Computed
chemical_list: D000933:Antifibrinolytic Agents; D009553:Nimodipine